Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 346 AL 360

Microbiota and Alzheimer's disease: mechanistic insights from a multi-organ perspective

Liao J, Mou H, Luo S, Shen L, Jiao B.

Transl Neurodegener. 2026 Feb 11;15(1):3. doi: 10.1186/s40035-026-00541-9.

Advances in Immune Cell Interactions and Natural Compounds Therapeutic Strategies in Alzheimer's Disease

Zhou S, Xu L, Dong J, Zhang X, Gao W, Luo H, Fang X.

Phytother Res. 2026 Apr;40(4):1837-1861. doi: 10.1002/ptr.70249. Epub 2026 Feb 2.

Targeting microglia-mediated neuroinflammation in Alzheimer's disease: mechanisms and therapeutic approaches

Li BF, Chen XY, Xie R, Mo YF, Wu YZ, Meng Y, Han XL, Chen MH, Peng YJ.

Front Immunol. 2026 May 13;17:1818802. doi: 10.3389/fimmu.2026.1818802. eCollection 2026.

The 3xTg-AD Mouse Model: A Comprehensive Tool for Understanding Alzheimer's Disease

Pattanayak A, Firdous SM.

Cell Mol Neurobiol. 2026 Feb 3;46(1):41. doi: 10.1007/s10571-025-01655-w.

The Role and Molecular Mechanism of Icaritin in the Treatment of Alzheimer's Disease

Zheng CB, Wu LZ, Song WY, Luo L, Cai JT, Huang ZH, Tian KQ.

Curr Med Chem. 2026;33(3):605-615. doi: 10.2174/0109298673354454250124074057.

The Potential of Coenzyme Q10 in Alzheimer's Disease: Reducing IL-17 Induced Inflammation and Oxidative Stress for Neuroprotection

Sharma H, Binte Ibrahim S, Al Noman A, Zohora UFT, Shifa FA, Siddika S, Tasneem S, Al Azad M, Pathak R.

Curr Drug Res Rev. 2026;18(1):92-105. doi: 10.2174/0125899775373406250411104442.

Targeting Microglial Phagocytosis for Alzheimer's Disease Management: Natural, Pharmacological, Nanoparticle, and Gene Therapy Approaches

Raghuvanshi S, Mazumder A, Das S.

CNS Neurol Disord Drug Targets. 2026;25(1):1-24. doi: 10.2174/0118715273378092250623064748.

Recent Advances of the Role of Dl-3-n-Butylphthalide in the Treatment of Alzheimer's Disease

Huang H, Wu J, Fang Z, Wang Y, Xie J, Guan Y.

Mol Neurobiol. 2026 Jan 3;63(1):340. doi: 10.1007/s12035-025-05616-8.

The aging gut-glia-immune axis in alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation

Mir PA, Kumar N, Bhutia GT, Chaudhary P, Kaur G, Gupta SK.

Geroscience. 2026 Apr;48(2):2201-2241. doi: 10.1007/s11357-025-02062-1. Epub 2026 Jan 12.

Challenges and Opportunities of Drug Delivery for Treatment of Alzheimer's Disease

Abd El-Fattah MA.

AAPS PharmSciTech. 2026 Jan 15;27(1):78. doi: 10.1208/s12249-025-03316-z.

Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player

Alanazi M, Al-Kuraishy HM, Hussain NR, Waheed HJ, Al-Gareeb AI, Albuhadily AK, Waheeb TS, Batiha GE.

Drug Dev Res. 2026 Apr;87(2):e70231. doi: 10.1002/ddr.70231.

The impact of the ketogenic diet on Alzheimer's disease progression

Grese Z, Naidu A, Silverglate BD, Grossberg GT.

Expert Rev Neurother. 2026 Mar;26(3):265-277. doi: 10.1080/14737175.2026.2621502. Epub 2026 Jan 27.

Mechanism of Exercise-Regulated Intestinal Flora for Alzheimer's Disease Based on Gut-Brain Axis

Zhao H, Wu W, Men X.

Nutrients. 2026 Jan 13;18(2):254. doi: 10.3390/nu18020254.

Neuroplasticity and Alzheimer's Disease

Gashtrodkhani AA, Shirkouhi SG, Khatami SS, Kamari F, Ghaedi S, Blaabjerg M, Andalib S.

J Integr Neurosci. 2026 Jan 26;25(1):48051. doi: 10.31083/JIN48051.

Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer's Disease: Advances and Future Directions

Dagla I, Gkikas F, Gikas E, Tsarbopoulos A.

Cells. 2026 Feb 4;15(3):295. doi: 10.3390/cells15030295.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias